Compare JFIN & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JFIN | RCEL |
|---|---|---|
| Founded | 2011 | N/A |
| Country | China | United States |
| Employees | N/A | 226 |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 330.9M | 132.0M |
| IPO Year | 2018 | N/A |
| Metric | JFIN | RCEL |
|---|---|---|
| Price | $5.90 | $4.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.88 |
| AVG Volume (30 Days) | 43.6K | ★ 216.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 13.22% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $21.69 |
| Revenue Next Year | N/A | $49.58 |
| P/E Ratio | $1.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.73 | $3.22 |
| 52 Week High | $18.70 | $10.28 |
| Indicator | JFIN | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 36.72 | 45.04 |
| Support Level | $5.81 | $4.11 |
| Resistance Level | $7.22 | $4.57 |
| Average True Range (ATR) | 0.25 | 0.37 |
| MACD | -0.03 | -0.08 |
| Stochastic Oscillator | 1.84 | 5.52 |
Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.